Follow the people · Insider
Robert J. Bitterman
Robert J. Bitterman files insider transactions with the SEC as a chairman, pres. & ceo of Phio Pharmaceuticals (PHIO). We hold 3 disclosed purchases and sales filed since 11 June 2013, 2 of them in the last 90 days.
- Files forPHIO
- Disclosed buys and sells3 in all, 2 in the last 90 days
- Last disclosure19 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 February 2019 — 18 August 2026Chairman, Pres. & CEO · Phio Pharmaceuticals (PHIO)35 Form 4 lines · source: SEC Form 4
- Filed 7 June 2013 — 1 August 2018Director · RXi Pharmaceuticals (RXII)17 Form 4 lines · source: SEC Form 4
Everything they disclosed
52 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 10,000 shares of Phio PharmaceuticalsSEC Form 419 August 2026Common Stock, $.0001 par value · traded 18 August 2026 · filed 19 August 2026
- ▲ bought on the open market 10,000 shares of Phio PharmaceuticalsSEC Form 429 June 2026Common Stock, $.0001 par value · traded 26 June 2026 · filed 29 June 2026
- was granted 120,000 shares of Phio PharmaceuticalsSEC Form 46 February 2026Common Stock, $.0001 par value · traded 5 February 2026 · filed 6 February 2026
- was granted 120,000 shares of Phio PharmaceuticalsSEC Form 46 February 2026Common Stock, $.0001 par value · traded 5 February 2026 · filed 6 February 2026
- ▲ bought on the open market 5,000 shares of Phio PharmaceuticalsSEC Form 42 January 2026Common Stock, $.0001 par value · traded 31 December 2025 · filed 2 January 2026
- ▲ bought on the open market 5,000 shares of Phio PharmaceuticalsSEC Form 42 January 2026Common Stock, $.0001 par value · traded 31 December 2025 · filed 2 January 2026
- ▲ bought on the open market 5,000 shares of Phio PharmaceuticalsSEC Form 429 December 2025Common Stock, $.0001 par value · traded 23 December 2025 · filed 29 December 2025
- ▲ bought on the open market 5,000 shares of Phio PharmaceuticalsSEC Form 424 November 2025Common Stock, $.0001 par value · traded 21 November 2025 · filed 24 November 2025
- ▲ bought on the open market 5,000 shares of Phio PharmaceuticalsSEC Form 419 November 2025Common Stock, $.0001 par value · traded 18 November 2025 · filed 19 November 2025
- had shares withheld for tax on 4,111 shares of Phio PharmaceuticalsSEC Form 415 September 2025Common Stock, $.0001 par value · traded 11 September 2025 · filed 15 September 2025
- was granted 250,000 shares of Phio PharmaceuticalsSEC Form 415 September 2025Common Stock, $.0001 par value · traded 11 September 2025 · filed 15 September 2025
- ▲ bought on the open market 2,000 shares of Phio PharmaceuticalsSEC Form 411 June 2025Common Stock, $0.0001 par value · traded 10 June 2025 · filed 11 June 2025
- ▲ bought on the open market 1,500 shares of Phio PharmaceuticalsSEC Form 410 June 2025Common Stock, $0.0001 par value · traded 9 June 2025 · filed 10 June 2025
- ▲ bought on the open market 3,000 shares of Phio PharmaceuticalsSEC Form 423 May 2025Common Stock, $0.0001 par value · traded 21 May 2025 · filed 23 May 2025
- ▲ bought on the open market 1,200 shares of Phio PharmaceuticalsSEC Form 423 May 2025Common Stock, $0.0001 par value · traded 22 May 2025 · filed 23 May 2025
- was granted 15,500 shares of Phio PharmaceuticalsSEC Form 413 September 2024Common Stock, $0.0001 par value · traded 11 September 2024 · filed 13 September 2024
- ▲ bought on the open market 1,000 shares of Phio PharmaceuticalsSEC Form 411 June 2024Common stock, $0.0001 par value · traded 7 June 2024 · filed 11 June 2024
- ▲ bought on the open market 1,000 shares of Phio PharmaceuticalsSEC Form 410 June 2024Common stock, $0.0001 par value · traded 6 June 2024 · filed 10 June 2024
- ▲ bought on the open market 2,500 shares of Phio PharmaceuticalsSEC Form 427 February 2024Common stock, $0.0001 par value · traded 26 February 2024 · filed 27 February 2024
- had shares withheld for tax on 1,804 shares of Phio PharmaceuticalsSEC Form 422 February 2024Common stock, $0.0001 par value · traded 20 February 2024 · filed 22 February 2024
- had shares withheld for tax on 917 shares of Phio PharmaceuticalsSEC Form 43 October 2023Common stock, $0.0001 par value · traded 1 October 2023 · filed 3 October 2023
- ▲ bought on the open market 1,000 shares of Phio PharmaceuticalsSEC Form 45 July 2023Common stock, $0.0001 par value · traded 30 June 2023 · filed 5 July 2023
- ▲ bought on the open market 1,000 shares of Phio PharmaceuticalsSEC Form 45 July 2023Common stock, $0.0001 par value · traded 1 July 2023 · filed 5 July 2023
- was granted 11,000 shares of Phio PharmaceuticalsSEC Form 422 February 2023Common stock, $0.0001 par value · traded 20 February 2023 · filed 22 February 2023
- ▲ bought on the open market 2,000 shares of Phio PharmaceuticalsSEC Form 415 December 2022Common stock, $0.0001 par value · traded 14 December 2022 · filed 15 December 2022
- ▲ bought on the open market 2,000 shares of Phio PharmaceuticalsSEC Form 48 December 2022Common stock, $0.0001 par value · traded 7 December 2022 · filed 8 December 2022
- ▲ bought on the open market 2,000 shares of Phio PharmaceuticalsSEC Form 46 December 2022Common stock, $0.0001 par value · traded 5 December 2022 · filed 6 December 2022
- ▲ bought on the open market 2,500 shares of Phio PharmaceuticalsSEC Form 429 November 2022Common stock, $0.0001 par value · traded 25 November 2022 · filed 29 November 2022
- ▲ bought on the open market 215 shares of Phio PharmaceuticalsSEC Form 429 November 2022Common stock, $0.0001 par value · traded 29 November 2022 · filed 29 November 2022
- ▲ bought on the open market 1 share of Phio PharmaceuticalsSEC Form 416 November 2022Series D Preferred Stock, $0.0001 par value · traded 16 November 2022 · filed 16 November 2022
- was granted 40,000 shares of Phio PharmaceuticalsSEC Form 43 October 2022Common stock, $0.0001 par value · traded 1 October 2022 · filed 3 October 2022
- was granted 10,000 shares of Phio PharmaceuticalsSEC Form 416 February 2022Common stock, $0.0001 par value · traded 15 February 2022 · filed 16 February 2022
- was granted 10,000 shares of Phio PharmaceuticalsSEC Form 43 March 2021Common stock, $0.0001 par value · traded 1 March 2021 · filed 3 March 2021
- was granted 300,000 shares of Phio PharmaceuticalsSEC Form 420 November 2019Common stock, $0.0001 par value · traded 18 November 2019 · filed 20 November 2019
- was granted 10,000 shares of Phio PharmaceuticalsSEC Form 415 February 2019Common stock · traded 13 February 2019 · filed 15 February 2019
- was granted 10,000 shares of RXi PharmaceuticalsSEC Form 43 August 2018Common Stock · traded 1 August 2018 · filed 3 August 2018
- was granted 2,000 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 43 February 2017Stock option (right to buy) · traded 1 February 2017 · filed 3 February 2017
- was granted 16,666 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 412 February 2016Stock option (right to buy) · traded 10 February 2016 · filed 12 February 2016
- was granted 37,500 shares of RXi PharmaceuticalsSEC Form 43 June 2015Common stock, $0.0001 par value · traded 2 June 2015 · filed 3 June 2015
- was granted 18,750 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 43 June 2015Overallotment purchase rights · traded 2 June 2015 · filed 3 June 2015
- was granted 18,750 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 43 June 2015Common stock warrants · traded 2 June 2015 · filed 3 June 2015
- was granted 16,666 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 42 June 2015Stock option (right to buy) · traded 1 June 2015 · filed 2 June 2015
- ▲ bought on the open market 3,147 shares of RXi PharmaceuticalsSEC Form 423 January 2015Common stock, $0.0001 par value · traded 22 January 2015 · filed 23 January 2015
- ▲ bought on the open market 1,853 shares of RXi PharmaceuticalsSEC Form 423 January 2015Common stock, $0.0001 par value · traded 22 January 2015 · filed 23 January 2015
- was granted 16,666 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 44 June 2014Stock Option (right to buy) · traded 2 June 2014 · filed 4 June 2014
- ▲ bought on the open market 500 shares of RXi PharmaceuticalsSEC Form 427 August 2013Common stock, $0.0001 par value · traded 26 August 2013 · filed 27 August 2013
- ▲ bought on the open market 500 shares of RXi PharmaceuticalsSEC Form 45 August 2013Common stock, par value $0.0001 · traded 5 August 2013 · filed 5 August 2013
- ▲ bought on the open market 200 shares of RXi PharmaceuticalsSEC Form 45 August 2013Common stock, par value $0.0001 · traded 5 August 2013 · filed 5 August 2013
- ▲ bought on the open market 100 shares of RXi PharmaceuticalsSEC Form 45 August 2013Common stock, par value $0.0001 · traded 5 August 2013 · filed 5 August 2013
- ▲ bought on the open market 100 shares of RXi PharmaceuticalsSEC Form 45 August 2013Common stock, par value $0.0001 · traded 5 August 2013 · filed 5 August 2013
- ▲ bought on the open market 100 shares of RXi PharmaceuticalsSEC Form 45 August 2013Common stock, par value $0.0001 · traded 5 August 2013 · filed 5 August 2013
- was granted 500,000 shares of RXi Pharmaceuticals (a derivative holding)SEC Form 411 June 2013Stock Option (right to buy) · traded 7 June 2013 · filed 11 June 2013
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.